A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain
Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, multi-center study of Tamiflu (Oseltamivir) will evaluate the
efficacy against viral activity, the effectiveness in resolving the disease symptoms, and the
safety and tolerability in patients with influenza. Patients with (H1N1) 2009 influenza
strain or influenza A are eligible for this study. Patients will be randomized to one of four
treatment regimens. Patients will receive oral doses of either 75 mg (adults) or 150 mg
(adults) of study drug twice daily for 5 or 10 consecutive days. The dose will be body
weight-adjusted for pediatric patients.